Revvity Inc
Отворен
СекторЗдравеопазване
100.52 0.9
Преглед
Промяна на цената на акция
24 ч
Минимум
99.09
Максимум
101.17
Приходи | -58M 41M |
|---|---|
Продажби | -61M 711M |
P/E Средно за сектора | 47.293 49.052 |
EPS | 1.06 |
Дивидентна доходност | 0.27 |
Марж на печалбата | 5.726 |
Служители | 11,000 |
EBITDA | -37M 181M |
Препоръки | Купи |
|---|---|
12-месечна прогноза | +4.1% upside |
Дивидентна доходност Средно за сектора | 0.27% 2.36% |
|---|---|
Следващи печалби | 27.07.2026 г. |
Следваща дата на дивидент | 7.08.2026 г. |
Следваща дата на екс-дивидент | 17.07.2026 г. |
Пазарна капитализация | 1.3B 11B |
|---|---|
Предишно отваряне | 99.62 |
Предишно затваряне | 100.52 |
Настроения в новините
By Acuity
10%
90%
3 / 342 Класиране в Healthcare
Revvity Inc Графика
Миналото представяне не гарантира бъдещи резултати.
Относно Revvity Inc
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.